ANKİLOZAN SPONDİLİTTE GÜNCEL TEDAVİ SEÇENEĞİ: TÜMÖR NEKROZ FAKTÖR ALFA ANTAGONİSTLERİ

Öz

Ankilozan spondilit (AS), aksiyal iskelet, entezis bölgeleri ve periferik eklemleri etkileyen kronik, sistemik, inflamatuar bir hastalıktır. AS tedavisinde farmakolojik tedavi yanı sıra eğitim ve fizik tedavi gibi farmakolojik olmayan tedavi metotları da uygulanmaktadır. Farmakolojik ajanlardan tümör nekroz faktör alfa (TNF-α) antagonistleri diğer tedavilere yanıt alınamayan hastalarda kullanılmaktadır. Bunlar infliksimab, etanersept, adalimumab ve golimumabdır. Bu ilaçlar hem klinik hem de laboratuar parametreleri üzerine etkinlik gösterebilmektedirler.
Ancak oluşabilecek yan etkiler nedeniyle dikkatli olunması ve hastaların düzenli takip edilmesi gerekmektedir.

Anahtar Kelimeler

• Ankilozan spondilit
• güncel tedavi
• TNF-α antagonistleri

Current Treatment Option in Ankylosing Spondylitis: Tumor Necrosis Factor Alpha Antagonists

Öz

Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that particularly involves axial skeleton, enthesis regions and peripheral joints. The pharmacological therapy as well as nonpharmacological therapy methods such as patient education and physical therapy are also applied in thetreatment of AS. Tumor necrosis factor alpha (TNF-α) antagonists, the pharmacological agents, are used in patients who fail to respond to other treatments. These are infliximab, etanercept, adalimumab, and golimumab. These drugs can show an efficiency on
both clinical and laboratory parameters. However, the side effects that may occur due caution and patients should be monitored regularly.

Anahtar Kelimeler

• Ankylosing spondylitis
• current treatment
• TNF-α antagonists

Kaynakça

1. Van Der Linden S, Van Der Hejide D, Braun J Ankylosing spondylitis. In: Harris ED,
2. Budd RC, Frestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB (Editors)
3. Kelley’s textbook of rheumatology, 7. Baskı, Philadelphia:Elsevier Saunders, 2005:
4. -1141.
5. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R.Comparison of serum
6. IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in
7. ankylosing spondylitis. Clin Rheumatol. 2007;26:211-5.
8. Reed MR, Taylor AL. Tumour necrosis factor inhibitors in ankylosing

9. spondylitis.Intern Med J. 2008;38:781-9.
10. Braun J, Sieper J. Ankylosing spondylitis.Lancet. 2007;369:1379-90.
11. Braun J, Van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez
12. E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman
13. RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP,
14. Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, Van
15. Drogen C, Van Royen B, Van der Heijde D. 2010 update of the ASAS/EULAR
16. recommendations for the management of ankylosing spondylitis. AnnRheumDis.
17. ;70:896-904.
18. Van der Linden S. Issues in the treatment of ankylosing spondylitis with non-steroidal
19. anti-inflammatory drugs. Wien Med Wochenschr. 2008;158:195-9.
20. Poddubnyy D, Van der Heijde D. Therapeutic controversies in spondyloarthritis:
21. nonsteroidal anti-inflammatory drugs.Rheum Dis Clin North Am. 2012;38:601-11.
22. Bodur H, Sivas F, Yılmaz Ö, Özgöçmen S, Günaydın R, Kaya T Ataman Ş, Altan L,
23. Altay Z, Aydoğ E, Birtane M, Borman P, Soy Buğdaycı D, Bütün B, Çakırbay H,
24. Duruöz T, Gürer G, Hepgüler S, Kamanlı A, Kuru Ö, Küçükdeveci A, Nacır B, Ölmez
25. N, Rezvani A, Çörekçi Yanık B. Türkiye romatizma araştırma savaş derneği ankilozan
26. spondilit ulusal tedavi önerileri.Turk J Rheumatol. 2011;26:173-86.
27. Kabasakal Y, Kitapcioglu G, Yargucu F, Taylan A, Argin M, Gumusdis G. Efficacy of
28. SLZ and MTX (aloneorcombination) on thetreatment of active sacroiliitis in early
29. AS.Rheumatol Int. 2009;29:1523-7.
30. Khalessi AA, Oh BC, Wang MY. Medical management of ankylosing
31. spondylitis.Neurosurg Focus. 2008;24:E4.
32. Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new?Curr
33. Rheumatol Rep. 2012;14:422-7.
34. Machado MA, Barbosa MM, Almeida AM, de Araujo VE, Kakehasi AM, Andrade EI,
35. Cherchiglia ML, Acurciof de A. Treatment of ankylosing spondylitis with TNF
36. blockers: a meta-analysis.Rheumatol Int. 2013;33:2199-213.
37. Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R,
38. Landewe R, Rudwaleit M, Braun J; Assessment of Spondylo Arthritis international
39. Society. 2010 Up date of the international ASAS recommendations for the use of anti-
40. TNF agents in patients with axial spondyloarthritis.Ann Rheum Dis. 2011;70:905-8.
41. Brandt J, Marzo-Ortega H, Emery P. Ankylosing spondylitis: new treatment modalities.
42. Best Pract Res Clin Rheumatol. 2006;20:559-70.
43. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H,
44. Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J. Treatment of
45. active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
46. Lancet. 2002;359:1187-93.
47. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun
48. J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy
49. Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis:
50. results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum.
51. ;52:582-91.
52. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S,
53. Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of
54. anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing
55. spondylitis over 5 years: evidence for different types of response.Ann Rheum Dis.
56. ;67:340-5.
57. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe
58. S, Schneider M, Sörensen H, Schmidt R, Sieper J, Braun J.Persistent clinical efficacy
59. and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response
60. predicts long-term outcome. Rheumatology (Oxford). 2011;50:1690-9.
61. Braun J, Breban M, Maksymowych WP. Therapy for ankylosing spondylitis: new
62. treatment modalities. Best Pract Res Clin Rheumatol. 2002;16:631-51.
63. De Stefano R, Frati E, De Quattro D, Menza L, Manganelli S. Low doses of etanercept
64. can be effective to maintain remission in ankylosing spondylitis patients.Clin
65. Rheumatol. 2013. [Epubahead of print]
66. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of
67. tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56
68. Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M,
69. Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of
70. etanercept treatment in patients with active ankylosing spondylitis.Arthritis Rheum.
71. ;48:1667-75.
72. Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term
73. outcome of patients with active ankylosing spondylitis with etanercept-sustaine
74. defficacy and safety after seven years. Arthritis Res Ther. 2013;15(3):R67.
75. Zochling J. Assessment and treatment of ankylosing spondylitis: current status and
76. future directions.Curr Opin Rheumatol. 2008;20(4):398-403.
77. Braun J, Sieper J. Biological therapies in the spondyloarthritides-the current
78. state.Rheumatology (Oxford). 2004;43:1072-84.
79. Van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA,
80. Mease PJ, Davis JC Jr; ATLAS Study Group.Adalimumab effectiveness for the
81. treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results
82. from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9.
83. Sieper J, Van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA,
84. Arora V, Pangan AL. Efficacy and safety of adalimumab in patients with nonradiographic
85. axial spondyloarthritis: results of a randomised placebo-controlled trial
86. (ABILITY-1).Ann Rheum Dis. 2013;72:815-22.
87. Sieper J, Van der Heijde D, Dougados M, Brown LS, Lavie F, Pangan AL. Early
88. response to adalimumab predicts long-term remission through 5 years of treatment in
89. patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:700-6.
90. Mittal M, Raychaudhuri SP. Golimumab and certolizumab: the two new anti-tumor
91. necrosis factor kids on the block. Indian J Dermatol Venereol Leprol. 2010;76:602-8.
92. Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S,
93. Hsia EC. Golimumab in patients with active rheumatoid arthritis despite
94. methotrexatetherapy: results through 2 years of the GO-FORWARD study extension. J
95. Rheumatol. 2013;40:1097-103.
96. Inman RD, Davis JC, Heijde DV, Diekman L, Sieper J, Kim SI, Mack M, Han J,
97. Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in
98. patients with ankylosing spondylitis: results of a randomized, double-blind, placebocontrolled,
99. phase III trial. Arthritis Rheum. 2008;58:3402-12.
100. Braun J, Baraliakos X, Hermann KG, Van der Heijde D, Inman RD, Deodhar AA,
101. Baratelle A, Xu S, Xu W, Hsu B. Golimumab reduces spinal inflammation in
102. ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE
103. study.Ann Rheum Dis. 2012;71:878-84.